These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 27745828

  • 1. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, Cornu C, Boussageon R.
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [Abstract] [Full Text] [Related]

  • 2. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.
    Cardiovasc Diabetol; 2017 Mar 01; 16(1):31. PubMed ID: 28249585
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ.
    Diabetes Metab; 2018 Nov 01; 44(5):386-392. PubMed ID: 30126735
    [Abstract] [Full Text] [Related]

  • 4. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Zhang F, Xu S, Tang L, Pan X, Tong N.
    Front Endocrinol (Lausanne); 2020 Nov 01; 11():288. PubMed ID: 32582019
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J.
    Diabetes Obes Metab; 2018 Jan 01; 20(1):113-120. PubMed ID: 28656707
    [Abstract] [Full Text] [Related]

  • 7. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S.
    PLoS One; 2017 Jan 01; 12(12):e0187537. PubMed ID: 29206832
    [Abstract] [Full Text] [Related]

  • 8. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec 01; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT.
    J Am Med Dir Assoc; 2016 Jan 01; 17(1):59-64. PubMed ID: 26612484
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
    Int J Cardiol; 2016 Oct 01; 220():595-601. PubMed ID: 27390996
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
    Cheng D, Fei Y, Liu Y, Li J, Chen Y, Wang X, Wang N.
    PLoS One; 2014 Oct 01; 9(10):e111543. PubMed ID: 25360775
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
    Savarese G, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM.
    Int J Cardiol; 2015 Feb 15; 181():239-44. PubMed ID: 25528528
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, Wayangankar SA, Bavry AA.
    Am J Cardiovasc Drugs; 2017 Apr 15; 17(2):143-155. PubMed ID: 27873238
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.
    Wu S, Hopper I, Skiba M, Krum H.
    Cardiovasc Ther; 2014 Aug 15; 32(4):147-58. PubMed ID: 24750644
    [Abstract] [Full Text] [Related]

  • 19. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH.
    Endocrinol Metab (Seoul); 2019 Mar 15; 34(1):80-92. PubMed ID: 30912341
    [Abstract] [Full Text] [Related]

  • 20. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ.
    Diabetes Metab; 2020 Jun 15; 46(3):186-196. PubMed ID: 32007623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.